NYSEAMERICAN:MTNB Matinas Biopharma (MTNB) Stock Price, News & Analysis $0.89 -0.03 (-3.08%) As of 12:02 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsOwnershipSEC Filings About Matinas Biopharma Stock (NYSEAMERICAN:MTNB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Matinas Biopharma alerts:Sign Up Key Stats Today's Range$0.89▼$0.9050-Day Range$0.92▼$3.0852-Week Range$0.81▼$18.75Volume14,317 shsAverage Volume129,668 shsMarket Capitalization$872.30 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company developing medicines based on its proprietary lipid nanocrystal (LNC) platform. The technology is designed to improve the delivery of pharmaceutical compounds, including drugs that may be difficult to administer through conventional oral formulations. The company’s lead product candidate is MAT2203, an investigational oral formulation of amphotericin B, an antifungal medicine commonly administered intravenously. Matinas is evaluating MAT2203 for potential use in serious systemic fungal infections, including cryptococcal meningitis and other invasive fungal diseases. The company has also explored applications of its LNC platform for delivering other anti-infective, nucleic acid and pharmaceutical compounds. Matinas BioPharma was established in the United States and conducts its research and development activities through collaborations and clinical programs intended to address significant unmet medical needs. Its product candidates remain investigational and are subject to clinical testing and regulatory review; they are not established substitutes for approved therapies unless authorized by applicable regulators.AI Generated. May Contain Errors. Read More Receive MTNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Matinas Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MTNB Stock News HeadlinesMatinas Biopharma (NYSEAMERICAN:MTNB) Stock Falls 14.6% - What's Next?November 3, 2026 | americanbankingnews.comGH Power Signs Multi-Year Hydrogen Offtake Agreement with Change Energy for Hamilton Facility OutputSeptember 14, 2026 | globenewswire.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 13 at 1:00 AM | Weiss Ratings (Ad)Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing StandardsSeptember 4, 2026 | globenewswire.comGH Power, Matinas BioPharma join forces to create NYSE-listed clean energy companyJuly 13, 2026 | msn.comMatinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement ...July 13, 2026 | markets.businessinsider.comMatinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity PharmaceuticalsJuly 13, 2026 | globenewswire.comMatinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain ComplianceJune 26, 2026 | globenewswire.comSee More Headlines MTNB Stock Analysis - Frequently Asked Questions How have MTNB shares performed this year? Matinas Biopharma's stock was trading at $8.79 on January 1st, 2026. Since then, MTNB shares have decreased by 89.6% and is now trading at $0.9184. How were Matinas Biopharma's earnings last quarter? Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) issued its earnings results on Wednesday, August, 14th. The company reported ($0.30) earnings per share for the quarter, meeting the consensus estimate of ($0.30). Read the conference call transcript. When did Matinas Biopharma's stock split? Matinas Biopharma shares reverse split on Monday, September 28th 2026.A 1-15 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, September 27th 2026. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Matinas Biopharma? Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Matinas Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Matinas Biopharma investors own include SCYNEXIS (SCYX), Tesla (TSLA), Viking Therapeutics (VKTX), Kushco (KSHB), Oncobiologics (OTLK), NIO (NIO) and Bionano Genomics (BNGO). Company Calendar Last Earnings8/13/2026Today11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 MTNB's financial health is in the Red zone, according to TradeSmith. MTNB has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:MTNB Previous SymbolNYSE:MTNB CIK1582554 Webmatinasbiopharma.com Phone(908) 484-8805FaxN/AEmployees2Year Founded2011Profitability EPS (Trailing Twelve Months)($3.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.35 million Net MarginsN/A Pretax MarginN/A Return on Equity-166.11% Return on Assets-102.20% Debt Debt-to-Equity RatioN/A Current Ratio0.85 Quick Ratio0.85 Sales & Book Value Annual Sales$1.10 million Price / Sales0.79 Cash FlowN/A Price / Cash FlowN/A Book Value$11.30 per share Price / Book0.08Miscellaneous Outstanding Shares980,000Free Float935,000Market Cap$872.30 thousand OptionableN/A Beta2.24 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NYSEAMERICAN:MTNB) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredA little-known law has been quietly applied to your savings for years.Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution...Monetary Gold | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
